Hepatitis delta antigen (HDAg), the only protein encoded by the hepatitis delta virus (HDV), binds specifically genomic and antigenomic strands of the HDV RNA. In a previous study, three recombinant HDAg subdomains were synthesized, covering residues 11 to 78, 79 to 163 and 164 to 212, and only the middle domain was shown to be responsible for the binding to HDV RNA. To investigate HDAg sequences involved in HDV RNA binding, we synthesized five peptides, 15 to 29 residues in length, and tested their ability to bind HDV RNA using a simple non-radioactive ELISA with digoxigenin-labelled HDV genomic or antigenomic RNA probes. The specificity of interactions was demonstrated by comparison with control peptides and non-HDV RNA probes, and with an inhibition assay using recombinant HDAg. The HDAg-binding domain found within the middle region (79 to 163) of HDAg was more finely mapped: it is located between residues 79 and 107. In addition, another domain (residues 2 to 27) of HDAg was also found to bind specifically to HDV RNA. These two peptides share sequence similarities at residues 2 to 10 and 97 to 107 with other RNA-binding domains.
Hepatitis delta virus (HDV) is a viroid-like RNA agent which is dependent on the envelope of hepatitis B virus (HBV) acting as a helper virus (Rizzetto et al., 1980) for packaging into virions . The HDV genome is a circular ssRNA of approximately 1'7 kb (Wang et al., 1986; Makino et al., 1987) able to fold on itself by base-pairing to form an unbranched rod-like structure (Chen et al., 1986; Kos et al., 1986; Wang et al., 1986; Branch et al., 1990) . The genome is replicated in the nucleus of infected cells by RNA-directed RNA synthesis, involving the synthesis of a complementary RNA (antigenome) which is also circular (Branch & Robertson, 1984; Chen et aI., 1986) .
Hepatitis delta antigen (HDAg) is the only known protein expressed by HDV. It is encoded by antigenomic RNA (Wang et al., 1986; Makino et al., 1987; Chang et aL, 1988 ; Kuo et al., 1988 ; Weiner et aL, 1988; Bergmann et al., 1989) . HDAg is found in the nucleus of infected cells and is associated with genomic RNA in the mature virion. Two types of HDAg of 195 (S) and 214 (L) amino acids co-exist in infected cells (Bergmann & Gerin, 1986; Bonino et al., 1986; Pohl et al., 1987; Weiner et al., 1988) . They are encoded by two RNA species: a single base change in the amber termination codon of the open reading frame of the S form leads to the synthesis of the L form which is 19 amino acids longer (Wang et al., 1986; Chao et al., 1990) . The S form is essential for HDV genome replication, whereas the L form acts as a dominant negative repressor of such replication (Macnaughton et aL, 1990a Glenn & White, 1991 ; Xia et al., 1992; Chang et al., 1992) . However, the L form is essential for the packaging of the genome into the HBV envelope Taylor et al., 1991 ; Wang et al., 1991 ; Chen et al., 1992; Ryu et al., 1992) . Previous studies have demonstrated that both the S and L forms of HDAg are able to bind either genomic or antigenomic HDV RNA (Chang et aL, 1988; Lin et al., 1990; Macnaughton et al., 1990b; Chao et al., 1991 ; Gowans et al., 1991; Lai et al., 1991; Taylor et al., 1991) . A requirement for this specific binding is that HDV RNA forms a rod-like structure . Specific HDAg/HDV RNA binding is believed to be involved in several steps in the virus life cycle, including (i) nuclear transport of the genomic strand during the early phase of cellular HDV infection, (ii) regulation of the replication of both genomic and antigenomic strands by the S and L forms and (iii) packaging of the genomic strand into the HBV envelope. To analyse protein sequences involved in this binding, Lin et al. (1990) genetically expressed three recombinant HDAg subdomains covering residues 11 to 78, 79 to 163 and 164 to 212. Only the central domain (residues 79 to 163) was found to bind HDV RNA (Lin et al., 1990) .
To characterize further HDAg sequences involved in (1987) . The different properties attributed to different amino acid sequences are represented: oligomerization by two stretches of the leucine zipper motif (L in shade) corresponding to residues 30 to 44 and 108 to 122 (Chao et al., 1990; Lin et al., 1990) ; nuclear transport by two nuclear localization signals (NLS1 and NLS2) (sequences in plain boxes) corresponding to residues 35 to 44, and 69 to 75 and 85 to 88, respectively Xia et al., 1992) ; the RNA-binding domain (sequence in dotted box) corresponding to residues 79 to 163 found by Lin et al. (1990) .
the binding to HDV RNA, we have developed a new non-radioactive assay using synthetic HDAg peptides bound to microtitre plates, digoxigenin-labelled RNAs and peroxidase-labelled anti-digoxigenin antibody. Specificity was monitored with non-pertinent peptides from human immunodeficiency virus (HIV) gp 120 protein and human hepatitis C virus (HCV) NS1 protein and with RNAs from bacteriophage 2 and plasmid pGEM-4. Five HDAg peptides, corresponding to residues 2 to 27, 79 to 107, 155 to 172, 168 to 182 and 189 to 211 (Fig.  1) were made with an automated peptide synthesizer (Applied Biosystem 431A) by a solid-phase procedure developed by Merrifield (1963) , using 9-fluorenylmethoxycarbonyl-protected amino acids and phydroxymethyl-phenoxyacetic resin. After synthesis, the resin support and the side-chain-protecting groups were removed by treatment with trifluoroacetic acid, and using scavengers. Peptides were purified by reverse phase chromatography using C8 columns (Aquapore octyl, 100 x 10 ram, 20 gm; Applied Biosystems). Peptide sequences were verified by amino acid analysis. All of the HDAg peptides and gpl20 peptide were previously shown to be recognized by human sera (Poisson et al., 1993; Baillou et al., 1993) . Digoxigenin-labelled genomic or antigenomic probes and two digoxigenin-labelled RNA control probes were prepared with the digoxigenin RNA labelling kit (SP6/T7) (Boehringer Mannheim). Digoxigenin-11-uridine 5' triphosphate (DIG-11-UTP; Boehringer Mannheim) was used as the labelled nucleotide. A 1248 bp cDNA of HDV RNA in plasmid pGEM-4 (pGBZ-1) (Kuo et al., 1988) was kindly provided by Dr John Taylor (Fox Chase Cancer Center, Philadelphia, Pa., U.S.A.). SP6 transcription of SalI-cut pGBZ-1 generated a partial genomic strand of 1220 nucleotides containing nucleotides 1420 to 1679 and 1 to 962. T7 transcription of EcoRI-cut pGBZ-1 generated a complementary partial antigenomic strand of 1242 bases. These partial genomic and antigenomic strands have a rod-like structure that has been shown to allow HDAg binding . Digoxigenin-labelled 2 RNA was obtained by SP6 transcription of a 1.37 kb 2 DNA fragment inserted into a pGEM plasmid (Promega) and digoxigenin-labelled plasmid pGEM-4 RNA was obtained by SP6 transcription of NheI-cut pGEM-4 (2"62 kb), as described above.
We have developed a new non-radioactive assay using peptides coated onto polystyrene microtitre plates (MaxiSorp; Nunc) at 10 gg/well in 0"01 M-PBS (0.15 M-NaC1 pH 7.4) or in 50 mM-bicarbonate buffer pH 9"6 for 20 h at 4 °C. After three washes in PBS containing 0"5% Tween 20 (PBS/TW), the wells were blocked with 50 mM-Tris-HC1 pH 7-5 containing 50 mM-NaC1, 1 mM-EDTA, 1 mM-DTT and 5 % milk powder (Blotto buffer) for 45 rain at 37 °C. After one wash in PBS/TW, 100 gl of DIG-11-UTP-labelled RNA probes at 0.1 lag/ml in Tris-buffered saline [0.01 M-Tris-HC1 pH 7, 450mM-NaC1, 1 mM-EDTA, 0.02% Ficoll, 0.02% polyvinylpyrrolidone (PVP), 0.1% yeast RNA] was added to each well and incubated for 1 h at room temperature. After three washes in PBS/TW, 100pl of peroxidaseconjugated F(ab')2 anti-digoxigenin (Boehringer Mannheim) diluted 1:2000 in 5 x PBS containing 5 % newborn calf serum, 5 % BSA and 0.5 % Tween 20 was added to each well and incubated for 1 h at 37 °C. After three washes in PBS/TW, a hydrogen peroxide-ophenylenediamine mixture was added for 15 min at room temperature in the dark. Colour development was stopped with 1 M-H~SO 4 and absorbance was read at 492 nm. Results are given as multiples of the value obtained with HIV and HCV control peptides in each assay.
Only peptides 2-27 and 79-107 bound to digoxigeninlabelled HDV genomic and antigenomic RNAs; they did not bind to control RNAs (Table 1) . Optimal binding was obtained in bicarbonate buffer for peptide 2-27 and in phosphate buffer for peptide 79-107 with values equal to 6'8-and 8-6-fold the cutoff for the genomic HDV (2) 2-27 2.9 6.8 4.6 6.2 1.2 1-5 1.5 2.4 79-107 8.6 7.8 9.9 7.6 1.2 1.3 2.5 2.4 155-172 0.7 0.9 1.0 1.0 1.0 1.1 0.9 1.2 168-182 0-7 0.9 0-7 0.9 0.8 1"0 0.8 0.9 189-211 0.9 0.6 0.8 0-7 0.9 1.1 0.9 0.9 * Results are given as multiples of the value obtained with control peptides.
~ (1), Coating buffer: PBS (1 x) pH 7.4. :~ (2), Coating buffer: bicarbonate pH 9.6. RNA and 6.2-and 9.9-fold the cutoff for the antigenomic RNA, respectively. Values obtained with the three other HDAg peptides with both genomic and antigenomic HDV RNA were equal or below the cutoff value (Table  1) . For all five HDAg peptides, values obtained with control RNA were between 0.8-and 2.5-fold the cutoff value. From dot blot analysis it has been postulated that HDAg binding to HDV RNA is approximately 15-fold greater than to mouse hepatitis virus RNA (Lai et al., 1991) and about 100-fold greater than binding to other RNAs . We used our assay to estimate semi-quantitatively the relative binding of HDAg to genomic and antigenomic HDV RNA and similarly to HDV RNA and non-HDV RNA. The ratios of binding between HDV RNAs and control RNAs were 5'8 (genomic) and 7.2 (antigenomic) for peptide 2-27 and 7.9 (genomic) and 10.6 (antigenomic) for peptide 79-107. The specificity of interactions between HDAg peptides and HDV RNAs was further assessed using recombinant HDAg in an inhibition test. The binding of RNAs to peptides was further analysed in the presence of recombinant HDAg. This recombinant HDAg (residues 1 to 204), expressed in Esherichia coli and purified to 98 % purity (determined by scanning a Coomassie bluestained SDS-polyacrylamide gel), is produced by Sorin Biomedica Laboratories (Calogero et al. 1993) . It was diluted in solutions containing 2 % acetic acid, to avoid aggregation (data not shown). After the coating and blocking steps described above, 100 gl of RNA probe diluted in 0.1 M-Tris-HC1 pH 7-0, 0.450 M-NaC1, 1 mM-EDTA, 0'02 % Ficoll, 0'02 % PVP buffer was added to each well in the presence of 2 gl of either 2 % acetic acid, recombinant HDAg, BSA or ovalbumin (each of these proteins at 1 mg/ml in 2 % acetic acid solution). The subsequent steps of the assay were performed as described above. Table 2 shows results obtained in our assay when recombinant HDAg, BSA or ovalbumin were added to HDV RNA. Only HDAg significantly inhibited the interaction between HDV RNA and HDV peptides. Although post-translational modifications such as phosphorylation at serine residues cannot be reproduced on synthetic peptides and can modify protein-nucleic acid interactions, our enzyme assay could be used for the rapid identification of binding domains. An RNAbinding domain has been described in the central third of the HDAg molecule (residues 79 to 163) (Lin et at., 1990) . However, in this previous study, the binding properties of the 10 N-terminal amino acids of HDAg were not investigated. Our results agree with these data and additionally (i) showed that another previously uncharacterized domain, the N-terminal part of HDAg (residues 2 to 27), is also a binding site for both genomic and antigenomic HDV RNA and (ii) mapped more finely the known HDV RNA-binding site in the central domain (79 to 163) to residues 79 to 107. We demonstrated that peptide 155-172, covering part of this previously studied domain, did not bind HDV RNAs. The region covering residues 107 to 155 may contain further binding site(s). However part of this region (residues 108 to 122) forms a leucine zipper involved in the polymerization of HDAg and is therefore unlikely to bind HDV RNAs as well. Finally, in accordance with a previous report (Lin et al., 1990) , the C-terminal sequence of HDAg, a hydrophobic domain containing only a few basic residues, studied with peptides 168 to 182 and 189 to 211, was unable to bind HDV RNAs.
Characteristic structural features found in many nucleic acid-binding proteins include a stretch of approximately 30 residues, rich in basic amino acids (thus having a positive charge that may interact with nucleic acid), followed by a leucine zipper motif (Halazonetis et al., 1988; Kouzarides & Ziff, 1988) . Moreover, R residues cause RNA-binding activity and it has been suggested that four R residues provide an effective RNA-binding motif (Hatton et al., 1992) . A consensus sequence, BOBRBJRRZZB, has been determined from 17 potential RNA-binding proteins, where B is a basic residue, O a non-basic polar residue, Z a charged residue and J an acidic residue (Lazinski et al., 1989) .
Interestingly, HDAg peptides 2-27 and 79-107 share sequence similarities with other RNA-binding proteins: the sequence 2 to 10 is similar to rat protein $26 and sequence 97 to 107 is similar to protein N of phage 22 (Lazinski et al., 1989; Fig. 2) . In addition, these regions include five and six residues respectively of the 11 amino acid consensus sequence (Lazinski et al., 1989; Fig. 2) . As expected, semi-quantification of RNA binding to peptides 2-27 and 70-107 did not show a significant difference between genomic and antigenomic HDV RNAs.
In conclusion, our study identifies two sequences involved in the RNA-binding activity of HDAg located between residues 2 to 27 and 79 to 107. These domains share strong sequence similarity with other RNA-binding proteins. The significance of these two distant HDV RNA-binding domains within the HDAg molecule remains to be determined; they may play different roles in the virus life cycle.
